



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Surgery*

Manuscript NO: 79695

Title: Recombinant Human Thrombopoietin Treatment in Patients with Chronic Liver Disease-related Thrombocytopenia undergoing invasive procedures: A Retrospective Study

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06143408

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Austria

Author's Country/Territory: China

Manuscript submission date: 2022-09-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-25 07:57

Reviewer performed review: 2022-10-07 23:44

Review time: 12 Days and 15 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Patients with end-stage liver disease often experience serious complications. The risk of bleeding during invasive procedures in patients with chronic liver disease is associated with platelet count, coagulopathy status, and the type of procedure. Recombinant human thrombopoietin is commonly used to treat primary immune thrombocytopenic purpura and immune thrombocytopenia caused by solid tumor chemotherapy; however, there are few reports on the use of recombinant human thrombopoietin in the treatment of chronic liver disease-related thrombocytopenia. This study is designed to analyze the efficacy of recombinant human thrombopoietin for the treatment of chronic liver disease-related thrombocytopenia to provide a reference for clinical treatment. The study is very well designed. The inclusion and exclusion criteria are reasonable, and described in detail. The results are interesting and well discussed. After a minor revision, this manuscript can be accepted for publication. Comments: 1. The manuscript requires a minor editing. Some minor language polishing should be revised. 2. Some data in the results section is repeated with the data in tables. Please check and make a revision. 3. A conclusion should be made in the main text. 4. Tables and figure are good. A minor editing to the tables is necessary.



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Surgery*

Manuscript NO: 79695

Title: Recombinant Human Thrombopoietin Treatment in Patients with Chronic Liver Disease-related Thrombocytopenia undergoing invasive procedures: A Retrospective Study

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06078865

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-09-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-25 07:58

Reviewer performed review: 2022-10-07 23:44

Review time: 12 Days and 15 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is an interesting study of the efficacy of recombinant human thrombopoietin in the treatment of patients with CLD-associated thrombocytopenia undergoing invasive procedures. The study is well performed and the results are interesting. The manuscript is overall well written. A minor editing is required before final publication. I have no specific comments to the authors. Thank you very much.